CS2009 is a trispecific antibody targeting PD-1, VEGFA, and CTLA-4, with the potential to be first- or best-in-class for major tumor types. Its differentiated molecular design combines three ...

Phase 2 results in inflammatory bowel disease hinted the therapy could be more potent than similar medicines from Merck and Roche, each of which were acquired in multibillion-dollar deals.

Duvakitug positive phase 2b results demonstrate best-in-class potential in ulcerative colitis and Crohn’s diseasePrimary endpoints met in ...

The result is a car that, Stegmaier says, will cover a whopping 5.2 miles per kWh and deliver 93% efficiency. That should ...